CLINICAL TRIALS PROFILE FOR AGGRASTAT
✉ Email this page to a colleague
All Clinical Trials for AGGRASTAT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00251576 ↗ | Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 1999-11-01 | A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner. Z-Phase: To evaluate early treatment of patients with long term chest pain (using an approved drug for 30 days, followed by an increased dose of the drug) as compared to patients (treated with diet and 4 months placebo followed by diet and approved drug) in patients who have experienced acute chest pain or heart attack. |
| NCT00300833 ↗ | Treating Acute MI Patients With Aggrastat on Their Way to Hospital | Unknown status | The Baruch Padeh Medical Center, Poriya | Phase 4 | 2006-01-01 | Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital. |
| NCT00383136 ↗ | FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab | Completed | University of Bologna | Phase 4 | 2003-06-01 | The elective("standard of care") treatment of ST - elevation acute myocardial infarction (STEMI) currently consists of primary angioplasty with stent implantation during administration of Abciximab, a inhibitor of GP IIb/IIIa platelet receptor. Tirofiban is another potent inhibitor of GP IIb/IIIa platelet receptor with an efficacy on platelet aggregation inhibition equal to or greater than Abciximab if a high dose bolus is used, i.e. 25 microg/kg, (platelet aggregation inhibition > 90% 15 minutes after infusion). It can therefore be hypothesized that this drug can improve the results of primary angioplasty to the same extent as Abciximab. The aim of this study is to compare the efficacy, in terms of myocardial reperfusion indices, of Abciximab and high dose of Tirofiban in primary angioplasty for STEMI, both in the case of treatment before transfer and of treatment in the catheterization laboratory during the procedure. The reference hypothesis for the study objective is the equivalence or the non-inferiority of Tirofiban with respect to Abciximab. |
| NCT00566891 ↗ | Safety of High-dose Tirofiban During Coronary Angioplasty | Completed | S. Anna Hospital | Phase 4 | 2007-12-01 | This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty. |
| NCT01109134 ↗ | Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients | Completed | The Society of Cardiac Health Protection | Phase 3 | 2008-09-01 | The aim of this randomized trial is to compare the efficacy of high dose tirofiban administered as either an intracoronary bolus alone or as an intravenous bolus followed by a maintenance infusion with respect to microvascular perfusion and long term left ventricular infarct size, volumes and function. |
| NCT01109134 ↗ | Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients | Completed | Kosuyolu Heart Hospital | Phase 3 | 2008-09-01 | The aim of this randomized trial is to compare the efficacy of high dose tirofiban administered as either an intracoronary bolus alone or as an intravenous bolus followed by a maintenance infusion with respect to microvascular perfusion and long term left ventricular infarct size, volumes and function. |
| NCT01245725 ↗ | Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention | Withdrawn | SCRI Development Innovations, LLC | Phase 3 | 1969-12-31 | The purpose of this study is to determine whether the efficacy of tirofiban (a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention (PCI) plus two hours after the procedure) is more effective than placebo in the setting of standard therapies (e.g. aspirin, a thienopyridine, and unfractionated heparin or bivalirudin) among patients undergoing PCI, as assessed by the incidence of adverse cardiac ischemic events defined as death, myocardial infarction (MI), and urgent target vessel revascularization (uTVR) within 48 hours following study drug initiation. A secondary objective of this study is to assess whether tirofiban (a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a PCI plus two hours after the procedure) is safe compared to placebo in the setting of standard therapies (e.g. aspirin, a thienopyridine, and unfractionated heparin or bivalirudin) among patients undergoing PCI, as assessed by the incidence of non-CABG-related TIMI major bleeding within 48 hours following study drug initiation. Patient enrollment is pending. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AGGRASTAT
Condition Name
Clinical Trial Locations for AGGRASTAT
Trials by Country
Clinical Trial Progress for AGGRASTAT
Clinical Trial Phase
Clinical Trial Sponsors for AGGRASTAT
Sponsor Name
